immunology
2017™ Meeting (2017/05/12-16))Abstracts
The Journal of JImmunology May 1, 2017, 198 (1 Supplement)
http://www.jimmunol.org/content/198/1_Supplement
[注] リスト書式:通し番号;タイトル;URL;タイトルにCRISPRが含まれていな場合はアブストラクトの該当部分を付加
1. The Nrf2
activators tBHQ and CDDO-Im have both Nrf2-dependent and – independent effects
on human Jurkat T cell activation, as determined by CRISPR-Cas9 gene editing
http://www.jimmunol.org/content/198/1_Supplement/124.4
2. Dissecting T
follicular helper cell development in vivo using CRISPR
http://www.jimmunol.org/content/198/1_Supplement/152.2
3. KEAP1 gene
editing using CRISPR/Cas9 for
therapeutic NRF2 activation in human T cells
http://www.jimmunol.org/content/198/1_Supplement/82.29
4. Investigating
the molecular mechanism of CRISPR-Cas
adaptation of Streptococcus thermophilus
http://www.jimmunol.org/content/198/1_Supplement/67.11
5. Optimization
of Gene Editing in Human Primary T Cells with Neon® Transfection System - “For CRISPR/Cas9
gene editing, more than 30% knock-in efficiency was observed while cleavage
efficiency at HPRT locus can be reached more than 70%.”
http://www.jimmunol.org/content/198/1_Supplement/73.24
6. Knockout
validation of antibodies to Ki67: a marker for cellular proliferation - “and the use of their KO cell lines generated
using CRISPR/Cas9 technology”
http://www.jimmunol.org/content/198/1_Supplement/213.10
7. Immunology
Antibody Validation: PTEN a target case in the use of human KO cell lines for
antibody validation - “and the use of
their KO cell lines generated using CRISPR/Cas9
technology”
http://www.jimmunol.org/content/198/1_Supplement/213.15
8. Hyperactivation
of PI3 kinase causes defects in human B-cell development and differentiation - “we generated a mouse model using CRISPR/Cas9 to introduce the common
disease-causing mutation (E1021K) into Pik3cd. “
http://www.jimmunol.org/content/198/1_Supplement/59.1
9. The role of
MHC class II polymorphisms for DM-mediated peptide editing and autoimmunity – “we introduced selected mutations in the
genome of the NOD mouse by CRISPR/Cas9
genomic editing.”
http://www.jimmunol.org/content/198/1_Supplement/156.24
コメント